ResMed vs Zoetis

ResMed (RMD), health care, and Zoetis (ZTS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

ResMed and Zoetis are valued at about the same: $33.5B and $33.9B. ResMed trades at 21.7 times earnings and Zoetis at 14.3. Over the past year ResMed's share price has moved -3.26% and Zoetis's -28.6%.

Key facts

ResMed market value
$33.5B
Zoetis market value
$33.9B
ResMed P/E
21.7
Zoetis P/E
14.3
ResMed revenue
$5.7BFY to 2026-06-30
Zoetis revenue
$9.5BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

ResMed vs Zoetis: every measure side by side
Measure ResMed Zoetis
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2026-06-302025-12-31
Size
Market cap$33.5Blower$33.9Bhigher
Revenue$5.7Blower$9.5Bhigher
Earnings$1.5Blower$2.7Bhigher
Employees11,370lower14,500higher
Total assets$9Blower$15.5Bhigher
Valuation
P/E21.7higher14.3lower
P/S5.9higher3.6lower
P/B5.6lower10.3higher
Dividend yield1.03%lower2.48%higher
Profitability
Operating margin33.4%—
Balance sheet
Net assets$6.6Bhigher$3.3Blower
Total liabilities$2.4Blower$12.1Bhigher
Total debt$659.4Mlower$9Bhigher
Cash on hand$1.5Blower$2.3Bhigher
Price change
Today-0.14%higher-1.08%lower
1 year-3.26%higher-28.6%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio. Who owns RMD · Who owns ZTS

Further comparisons

Learn

Questions and answers

Which is bigger, ResMed or Zoetis?

By market value, Zoetis is the larger: $33.9B against $33.5B for ResMed. By revenue in its latest fiscal year, Zoetis is the larger: $9.5B against $5.7B for ResMed.

Which has the higher P/E ratio?

ResMed: 21.7, against 14.3 for Zoetis. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

Zoetis: 2.48%, against 1.03% for ResMed. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Zoetis: $9B, against $659.4M for ResMed. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both ResMed and Zoetis?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds ResMed and 13 hold Zoetis.

Cite this page

Funkfolio, “ResMed vs Zoetis”, data as of 18 November 2026. https://funkfolio.com/compare/rmd-vs-zts

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.